Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

Trial Profile

Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top